Tagged with Pierre Fabre

Pharma Faces Mouloud Boukhachab, Pierre Fabre’s managing director for Africa, the Middle East and Turkey, took on the new responsibilities of his current position in March 2020 at the beginning of the coronavirus pandemic. In a recent interview with PharmaBoardroom, Boukhachab outlined the career trajectory that has led him to his current…

MEA Pierre Fabre’s recently appointed head for Africa, the Middle East and Turkey, Mouloud Boukhachab, outlines his career trajectory, having worked and managed in geographies as diverse as BeNeLux and Morocco. Boukhachab also states his priorities for his new position and his strategy for navigating the ongoing coronavirus pandemic and lockdown…

Morocco Pierre Behnam, general manager of Pierre Fabre in Morocco, breaks down the strong and long-standing footprint of the group in the country in the medical and dermo-cosmetic fields. On the medical side, he talks about the amazing progress Morocco has made in the prevention and treatment of cancer, and his…

Czech Republic Roman Dusil, GM of Pierre Fabre Laboratories in the Czech Republic and Slovakia, shares how the Czech affiliate is ahead of Pierre Fabre’s global transformation of the convergence between the dermo-cosmetic and pharmaceutical verticals. In dermo-cosmetics, Dusil explains the dynamics of the Czech pharmacy market and emphasizes the company’s efforts to…

UAE From Turkey to Tajikistan, Bangladesh to Bahrain, and Russia to Rwanda, multinational pharma firms are increasingly situating wide-ranging management responsibilities in the UAE. The following is an inexhaustive list of some of the widely varying geographies being managed from the UAE, as well as insights from the executives overseeing them.…

UAE Pierre Fabre, the French dermo-cosmetics giant, is banking on its tradition of quality to continue disrupting the emerging markets. Naim Hanna, managing director for the Middle East and Gulf region, provides insights into the region’s competitive landscape, analyzes the most recent consumer trends and explains how the “Taking Care, Living…

France With a feel-good factor sweeping French innovative pharma, the country’s iconic mid-cap biopharma standard-bearers are once more on the rise. These medium-sized national champions form part of G5 Santé, a club of companies altogether contributing some EUR 4.5 billion (USD 5 billion) worth of turnover to the home market and…

France The latest issue of Healthcare & Life Sciences Review France follows on from our March 2019 report and takes a closer look at the wider French life sciences value chain and the spirit of innovation and reform sweeping the nation.   A reform-minded and business-oriented administration under President Emmanuel Macron…

France Iconic French skincare specialist, Pierre Fabre has been enjoying a hot streak of late, with its dermo-cosmetics business registering hefty sales growth of more than EUR 350 (USD 392) million since 2014. It is, however, the company’s unique positioning right at the confluence between the worlds of medicines and cosmetics…

France Éric Ducournau, global CEO of Pierre Fabre Group, the second largest dermo-cosmetic company worldwide and the third-largest French pharmaceutical laboratory, provides insights into the group’s on-going internationalization and its emerging markets strategy, while reaffirming Pierre Fabre’s commitment to France’s healthcare innovation ecosystem. As illustrated by the group’s new motto ‘Taking…

Europe Bringing together insights from the heads of some of Europe’s most prominent mid-cap pharma firms. The leaders of Ipsen, Genmab, Pierre Fabre, Esteve and Servier outline the strategic directions in which their companies are turning and how they are planning to ensure a successful future.   David Meek, Ipsen David…

China Tian Wee Ng, managing director (Asia-Pacific) for Pierre Fabre Medicament, shares insight on how the business has evolved in the region, moving from an opportunistic approach to a more strategic one, since his appointment in 2016. He also discusses the value of Pierre Fabre’s oncology portfolio for the region and…